瑞巴派特治疗Hp相关性十二指肠溃疡效果评价  

Evaluation of the effect of rebamipide in the treatment of Hp-related duodenal ulcer

作　　者：赵锐豪 樊宏伟[1] 孙晓[1] ZHAO Rui-hao;FAN Hong-wei;SUN Xiao(First Ward of Department of Gastroenterology,Nanyang Central Hospital,Nanyang 473000,China)

机构地区：[1]南阳市中心医院消化内科一病区,河南南阳473000

出　　处：《社区医学杂志》2022年第9期505-509,共5页Journal Of Community Medicine

摘　　要：目的探讨联合瑞巴派特治疗在幽门螺杆菌(Hp)相关性十二指肠溃疡患者中的应用效果。方法选取2020-07-01-2021-07-19南阳市中心医院Hp相关性十二指肠溃疡患者101例,根据随机数字表法分为观察组(n=51)、对照组(n=50)。2组均给予常规四联疗法,对照组联合双歧杆菌四联活菌片治疗,0.5 g/次,2次/d,观察组在以上基础上,联合瑞巴派特治疗,0.1 g/次,3次/d。干预1个月后,通过门诊复查统计相关资料。对比2组疗效、Hp根除率、不良反应发生率、治疗前后胃部分泌物[胃泌素(GAS)、胃蛋白酶原Ⅰ(PGⅠ)、胃动素(MTL)、胃蛋白酶原Ⅱ(PGⅡ)]、病情相关因子[白细胞介素-6(IL-6)、表皮细胞生长因子(EGF)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)水平、肿瘤坏死因子-α(TNF-α)]、免疫蛋白[免疫球蛋白A(IgA)、G(IgG)]水平及不良反应发生率。对照组失访1例,观察组失访2例,2组均49例患者完成干预。结果观察组总有效率为87.76%(43/49),高于对照组的69.39%(34/49),差异有统计学意义,χ^(2)=4.909,P=0.027;Hp根除率为89.80%(44/49),高于对照组的65.31%(32/49),差异有统计学意义,χ^(2)=8.440,P=0.004。治疗后观察组GAS水平为(126.37±13.96)ng/L,低于对照组的(147.53±16.58)ng/L,差异有统计学意义,F=26.482,P<0.001;PGⅠ水平为(226.51±23.13)μg/L,低于对照组的(252.34±28.67)μg/L,差异有统计学意义,F=9.466,P<0.001;PGⅡ水平为(13.96±1.31)μg/L,低于对照组的(16.53±1.25)μg/L,差异有统计学意义,F=12.52,P<0.001;IL-6水平为(27.68±4.26)ng/L,低于对照组的(34.95±6.21)ng/L,差异有统计学意义,F=6.758,P<0.001;TNF-α水平为(25.94±10.23)pg/L,低于对照组的(36.18±11.97)pg/L,差异有统计学意义,F=14.552,P<0.001;MMP-9水平为(79.69±13.56)g/L,低于对照组的(105.21±13.54)g/L,差异有统计学意义,F=9.322,P<0.001。治疗后观察组MTL水平为(421.34±41.05)ng/L,高于对照组的(345.56±40.67)ng/L,差异有统计学意义,F=15.387Objective This study investigated the effect of combined rebamipide treatment in patients with Helicobacter pylori(Hp)-related duodenal ulcer.Methods A total of 101 patients with Hp-related duodenal ulcer in Nanyang Central Hospital from 2020-07-01 to 2021-07-19 were selected and divided into observation group(n=51)and control group(n=50)according to the random number table method.Both groups were given conventional quadruple therapy,the control group was treated with bifidobacteria quadruple viable tablet,0.5 g/time,2 times/d,and the observation group was treated with rebamipide on the basis of the above,0.1 g/time,3 times/d.After 1 month of intervention,the relevant data were re-examined through the outpatient clinic.The efficacy,Hp eradication rate,adverse reaction rate,gastric secretions before and after treatment,including gastrin(GAS),pepsinogen I(PGⅠ),motilin(MTL),pepsinogenⅡ(PGⅡ)were compared between the two groups.Disease-related factors,such as interleukin-6(IL-6),epidermal growth factor(EGF),vascular endothelial growth factor(VEGF),matrix metalloproteinase-9(MMP-9)levels,tumor necrosis factor-α(TNF-α),immunoglobulin A(IgA)and G(IgG)levels and adverse reaction rates were also compared between the two groups.Only1case in the control group was lost to follow-up,2cases in the observation group were lost to follow-up,and 49patients in both groups completed the intervention.Results The total effective rate in the observation group was 87.76%(43/49)higher than 69.39%in the control group(34/49),the difference was statistically significant,χ^(2)=4.909,P=0.027;Hperadication rate was 89.80%(44/49),higher than 65.31%(32/49)of the control group,the difference was statistically significant,χ^(2)=8.440,P=0.004.After treatment,the GAS level of the observation group was(126.37±13.96)ng/L,which was lower than that of the control group(147.53±16.58)ng/L,and the difference was statistically significant,F=26.482,P<0.001;PGⅠlevel was(226.51±23.13)μg/L,lower than that of the control group(252.34±28.67)μg/L,

关 键 词：瑞巴派特 双歧杆菌 幽门螺杆菌 免疫功能 根除率 

分 类 号：R573.1[医药卫生—消化系统]